Skip to main
PCVX

Vaxcyte (PCVX) Stock Forecast & Price Target

Vaxcyte (PCVX) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 0%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Vaxcyte Inc is positioned favorably due to its successful Phase 3 clinical trials and anticipated regulatory support, which could enhance the company’s market valuation and likelihood of commercial success, irrespective of ongoing Phase 2 data. The firm's peak revenue estimate has been slightly adjusted upward to $6.8 billion for 2040, reflecting a positive outlook on market adoption and dynamics of its flagship product VAX-31, set to launch in 2028. The extensive market opportunity for pneumococcal conjugate vaccines, particularly with new recommendations for adults over 50 by the ACIP, underscores Vaxcyte's potential for substantial growth, driven further by positive clinical outcomes expected from its ongoing trials.

Bears say

Vaxcyte’s stock outlook is negatively impacted by the underwhelming expectations surrounding the VAX-24 Phase 2 trial in infants, which may dampen investor confidence in the company’s potential within the larger pediatric vaccine market. Additionally, the prevailing tougher stance on vaccines from regulatory authorities adds to the uncertainty faced by the company, potentially complicating its market entry and acceptance for its vaccine candidates. Furthermore, Vaxcyte faces inherent risks associated with clinical trials, including the possibility of failing to demonstrate safety and efficacy, which could severely limit its commercial prospects.

Vaxcyte (PCVX) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 0% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vaxcyte (PCVX) Forecast

Analysts have given Vaxcyte (PCVX) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Vaxcyte (PCVX) has a Strong Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $106, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $106, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vaxcyte (PCVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.